• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.

作者信息

Shukla S, Sauna Z E, Ambudkar S V

出版信息

Leukemia. 2008 Feb;22(2):445-7. doi: 10.1038/sj.leu.2404897. Epub 2007 Aug 9.

DOI:10.1038/sj.leu.2404897
PMID:17690695
Abstract
摘要

相似文献

1
Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.伊马替尼在多药耐药相关的ABC药物转运蛋白ABCB1（P-糖蛋白）和ABCG2的转运底物位点相互作用的证据。
Leukemia. 2008 Feb;22(2):445-7. doi: 10.1038/sj.leu.2404897. Epub 2007 Aug 9.
2
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.摄取性药物转运体hOCT1的表达是慢性髓性白血病中对伊马替尼反应的重要临床决定因素。
Clin Pharmacol Ther. 2008 Feb;83(2):258-64. doi: 10.1038/sj.clpt.6100268. Epub 2007 Jun 13.
3
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.厄洛替尼（特罗凯，OSI-774）可拮抗ATP结合盒转运体B成员1和ATP结合盒转运体G成员2介导的耐药性。
Cancer Res. 2007 Nov 15;67(22):11012-20. doi: 10.1158/0008-5472.CAN-07-2686.
4
MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.伊马替尼治疗下 K-562 细胞的 microRNA 谱分析：miR-212 和 miR-328 对 ABCG2 表达的影响。
Pharmacogenet Genomics. 2012 Mar;22(3):198-205. doi: 10.1097/FPC.0b013e328350012b.
5
A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.一种新型的肠道细胞培养模型，用于区分 P-糖蛋白和 BCRP 对伊马替尼等底物转运的相对贡献。
Mol Pharm. 2010 Oct 4;7(5):1618-28. doi: 10.1021/mp100040f. Epub 2010 Aug 11.
6
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.比较三磷酸腺苷结合盒转运蛋白与酪氨酸激酶抑制剂伊马替尼、尼洛替尼和达沙替尼的相互作用。
Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27.
7
Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.酪氨酸激酶抑制剂通过 PI3K/Akt 信号通路影响 EGFR 阳性 MDCK BCRP 细胞中 ABCG2 的表达。
ChemMedChem. 2012 Apr;7(4):650-62. doi: 10.1002/cmdc.201100543. Epub 2012 Feb 22.
8
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.ABCB1 和 ABCG2 外排转运体与伊马替尼、尼洛替尼和达沙替尼的相互作用。
Clin Pharmacol Ther. 2014 Mar;95(3):294-306. doi: 10.1038/clpt.2013.208. Epub 2013 Oct 9.
9
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.舒尼替尼（索坦，SU11248）是一种小分子受体酪氨酸激酶抑制剂，可阻断ATP结合盒（ABC）转运蛋白P-糖蛋白（ABCB1）和ABCG2的功能。
Drug Metab Dispos. 2009 Feb;37(2):359-65. doi: 10.1124/dmd.108.024612. Epub 2008 Oct 29.
10
Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.姜黄素的主要代谢产物四氢姜黄素对三种ABC药物转运蛋白，即P-糖蛋白（ABCB1）、米托蒽醌耐药蛋白（ABCG2）和多药耐药蛋白1（ABCC1）功能的调节作用。
Mol Cell Biochem. 2007 Feb;296(1-2):85-95. doi: 10.1007/s11010-006-9302-8. Epub 2006 Sep 8.

引用本文的文献

1
Non-coding RNAs: Emerging contributors to chemoresistance in chronic myeloid leukemia.非编码RNA：慢性髓性白血病化疗耐药的新因素
Leuk Res Rep. 2025 May 9;23:100513. doi: 10.1016/j.lrr.2025.100513. eCollection 2025.
2
Evaluation of Novel Benzo-annelated 1,4-dihydropyridines as MDR Modulators in Cancer Cells.新型苯并稠合1,4-二氢吡啶作为癌细胞中多药耐药调节剂的评估
Anticancer Agents Med Chem. 2024;24(14):1047-1055. doi: 10.2174/0118715206314406240502054139.
3
1,4-Naphthoquinone (CNN1) Induces Apoptosis through DNA Damage and Promotes Upregulation of in Leukemia Multidrug Resistant Cell Line.
1,4-萘醌（CNN1）通过 DNA 损伤诱导细胞凋亡，并促进白血病多药耐药细胞系中 上调。
Int J Mol Sci. 2022 Jul 23;23(15):8105. doi: 10.3390/ijms23158105.
4
Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia.依拉曲沙与伊马替尼联合使用可调节慢性髓性白血病中与药物外排转运蛋白相关的耐药性。
Biomedicines. 2022 May 17;10(5):1158. doi: 10.3390/biomedicines10051158.
5
Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells.英菲格拉替尼（BGJ 398），一种泛FGFR抑制剂，作用于P-糖蛋白并增加化疗诱导的多药耐药肿瘤细胞死亡率。
Biomedicines. 2022 Mar 3;10(3):601. doi: 10.3390/biomedicines10030601.
6
Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.与慢性髓性白血病治疗相关的酪氨酸激酶抑制剂的转运与代谢：综述
Mol Cell Biochem. 2022 Apr;477(4):1261-1279. doi: 10.1007/s11010-022-04376-6. Epub 2022 Feb 7.
7
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.克服对激酶抑制剂的耐药性：慢性髓性白血病的范例
Onco Targets Ther. 2022 Jan 25;15:103-116. doi: 10.2147/OTT.S289306. eCollection 2022.
8
The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors.人类ATP结合盒转运蛋白P-糖蛋白和ABCG2在癌症及内源性位点多药耐药中的作用：基于结构的抑制剂药物设计的未来机遇
Cancer Drug Resist. 2021;4(4):784-804. doi: 10.20517/cdr.2021.19. Epub 2021 Aug 4.
9
Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.Abl 激酶的突变改变了药物结合动力学，提示了伊马替尼耐药的新机制。
Proc Natl Acad Sci U S A. 2021 Nov 16;118(46). doi: 10.1073/pnas.2111451118.
10
Fluorescent kinase inhibitors as probes in cancer.荧光激酶抑制剂作为癌症研究中的探针
Chem Soc Rev. 2021 Sep 7;50(17):9794-9816. doi: 10.1039/d1cs00017a. Epub 2021 Jul 22.